Infections and Hypogammaglobulinemia with Low‑Dose Rituximab in Myasthenia Gravis — Full Text Not

Study background and objectives (not reported)

The supplied source content does not contain the study background, rationale, or explicit objectives for the article examining myasthenia gravis patients treated with low‑dose rituximab and outcomes related to infections and hypogammaglobulinemia. The material provided consists of journal navigation and section lists rather than the article body; therefore, the authors' stated aims, hypothesis, or clinical questions were not reported and cannot be summarized from the source.

Methods and cohort description (not reported)

Details commonly included in a cohort study — such as study design (prospective or retrospective), enrollment period, setting (single center or multicenter), sample size, inclusion and exclusion criteria, baseline patient characteristics (age, sex, disease duration, antibody status), and concurrent therapies — were not present in the supplied content. Information on the low‑dose rituximab regimen used (dose, schedule, maintenance dosing), monitoring protocols, follow‑up duration, or how missing data were handled was not reported in the provided source.

Because these methodological elements are absent, it is not possible to evaluate internal validity, selection bias, or the generalizability of results from the supplied material.

Definitions and measurements: infections and hypogammaglobulinemia (not reported)

The source content did not include operational definitions or measurement details. Specifically, the following were not reported in the provided text:

• How infections were defined and classified (e.g., site, microbiologically confirmed vs clinically suspected, severity grading, hospitalization requirement).
• Laboratory methods or thresholds used to define hypogammaglobulinemia (e.g., total IgG cutoff values or subclass measurements), timing of immunoglobulin testing relative to rituximab dosing, and whether baseline immunoglobulin levels were reported.
• Use of prophylactic measures (vaccination status, antimicrobial prophylaxis, immunoglobulin replacement) and criteria for initiating replacement therapy.

Without these specifics, the presence, timing, and clinical relevance of any reported immunologic changes or infectious events cannot be interpreted from the available source.

Results: infections, immunoglobulin changes, and associations (not reported)

The provided source did not include numerical results, tables, figures, or narrative results discussing rates of infections, incidence of hypogammaglobulinemia, temporal relationships with low‑dose rituximab, or statistical associations between variables. The following key result elements were not present in the source and therefore cannot be restated:

• Number or proportion of patients who developed infections and their severity.
• Types or sites of infections and whether any opportunistic pathogens were identified.
• Frequency and magnitude of immunoglobulin declines and the timing relative to treatment.
• Any identified risk factors for infection or hypogammaglobulinemia (patient characteristics, cumulative dose, prior immunosuppression).
• Outcomes such as infection‑related hospitalization, need for immunoglobulin replacement, or therapy discontinuation.

Safety, management, and clinical implications (not reported)

Recommendations about monitoring strategies, thresholds for intervention (for example, when to start Ig replacement), or practical guidance for clinicians treating myasthenia gravis patients with rituximab were not included in the supplied content. Likewise, any discussion on balancing disease control with infectious risk, or suggested prophylactic measures, was not reported in the source provided here.

Limitations and areas needing clarification (not reported)

The full article likely contains its own limitations and discussion of generalizability; however, these were not accessible in the supplied material. Because the article text and data were not present, readers cannot assess common study limitations such as sample size constraints, retrospective design, ascertainment bias for infections, or incomplete immunologic follow‑up.

How to access the full article and recommended next steps

The content provided to this summary is journal site navigation and does not include the article's main text. For clinicians, researchers, or readers who require the study's actual data, methods, and conclusions, the following steps are recommended:

• Access the Frontiers in Immunology article page directly (the DOI or journal site) to obtain the full text, figures, and supplementary material.
• Review the Methods section for definitions of infection and hypogammaglobulinemia, the rituximab dosing regimen, and monitoring schedules to understand applicability to clinical practice.
• Consult the Results and Discussion for actual rates of infection and immunoglobulin changes and any authors' recommendations about monitoring or prophylaxis.

Note: This rewritten summary and the accompanying table of contents reflect only what was present in the supplied source content. Specific study findings, numeric results, or authors' interpretations were not reported in the source provided and therefore are not included here. To obtain actionable clinical detail, please retrieve and read the full published article on the journal platform.